Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms
Nicolas Hoertel, Marina Sánchez‐Rico, Céline Cougoule, Erich Gulbins, Johannes Kornhuber, Alexander Carpinteiro, Katrin Anne Becker, Angela M. Reiersen, Eric J. Lenze, David Seftel, Cédric Lemogne, Frédéric Limosin
Topics & Concepts
CeramideRepurposingCoronavirus disease 2019 (COVID-19)Acid sphingomyelinaseSphingomyelinPharmacology2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Drug repositioningChemistryMedicineBiochemistryBiologyVirologyCholesterolDrugApoptosisInternal medicineDiseaseEcologyOutbreakInfectious disease (medical specialty)Sphingolipid Metabolism and SignalingPharmacological Receptor Mechanisms and EffectsTryptophan and brain disorders